About the 2nd Annual IOBDLI Forum
The 2nd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.
2016 Programme will feature sessions on:
Confirmed Keynotes Include:
“Driving Advancement in Cancer Immunotherapy”
by Sophie Kornowski-Bonnet, Head of Roche Partnering, F. Hoffmann-La Roche AG
"Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and prospects for Cures" - Abstract
by James Allison, Chairman, Department of Immunology, Director, Immunology Platform, MD Anderson Cancer Center
“CAR and TCR-engineered T-cells for the Treatment of Hematologic Malignancies and Solid Tumors”
by Jeff Wiezorek, Senior Vice President, Clinical Development, Kite Pharma, Inc.
"From the clinic to the lab: Investigating immune responses to immune checkpoint therapies" - Abstract
by Padmanee Sharma, Scientific Director, Immunotherapy Platform, Professor, Department of Genitourinary Medical Oncology
Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center
Confirmed Speakers & Chairs Include:
Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 10 or 20 minute presentations, also available as live-stream or recorded and edited.
Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Chicago forum provides the additional interaction with the academic/scientific and patient advocacy communities.
Confirmed Presenters for 2016 Include:
To view company profiles please click HERE.
Sponsorship and Exhibition:
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.
Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.
To learn more about presenting, exhibition or sponsorship opportunities, please contact: Silvia Kar on +44 203 463 4890 or by email: Silvia.
Pharma Licensing Groups in 2016:
Financial / Advisory / Investors in 2016:
Altius Strategy Consulting
Aquilo Capital Management
Biotech Alliances International, Inc.
Chardan Capital Markets, LLC
Cowen and Company
Dawson James Securities, Inc.
EcoR1 Capital, LLC
FBR & Co.
GreenPeptide Co., Ltd.
H.C. Wainwright & Co., LLC
Katan Family Office
Laidlaw & Company
Loncar Investment, LLC
MedPro Investors, LLC
Merchant Liquidity Fund, LP
New Leaf Venture Partners
Nextech Invest Ltd.
Noble Life Science Partners
Oppenheimer & Co., Inc.
Oslo Life Science Advisors
Oxford Bioscience Partners
QVT Financial LP
SMR Consulting GmbH
Stifel Financial Corp.
SunTrust Robinson Humphrey
Vertex Healthcare Ventures
VI Partners AG
Yorkville Advisors, LLC